Bulk Quote Inquiry

COV-VM1SM-100μg / Inquiry

COV-VM1SM-500μg / Inquiry

COV-VM1SM-1mg / Inquiry

SARS-COV-2 Spike S1 (N501Y,K417N,E484K) Protein

Product Info

Recombinant SARS-COV-2 Spike S1 (N501Y,K417N,E484K) Protein is expressed from Expi293 with His tag at the C-terminal. It contains Val16-Arg685(N501Y,K417N,E484K).[Accession | YP_009724390.1]

Molecular Weight

The protein has a predicted MW of 75.9 kDa. Due to glycosylation, the protein migrates to 90-130 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC


Supplied as 0.22μm filtered solution in PBS (pH 7.4).


The product should be stored at -70℃. Please do not repeated freeze-thaw cycles.

Assay Data
Tris-Bis PAGE

SARS-COV-2 Spike S1 (N501Y,K417N,E484K) on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.


The purity of SARS-COV-2 Spike S1 (N501Y,K417N,E484K) is greater than 95% as determined by SEC-HPLC.


SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) as a receptor to invade cells. It has been reported that the UK and South African strains may have higher transmission capabilities, eventually in part due to amino acid substitutions on the SARS-CoV-2 Spike protein.The results of a study show the N501Y replacement in this region of the interface (present in both the UK and South African strains) should be favorable for the interaction with ACE2, while the K417N and E484K substitutions (South African strain) would seem neutral or even unfavorable.


S1 protein;Spike glycoprotein Subunit1;S glycoprotein Subunit1;Spike protein S1


(1)Villoutreix BO, Calvez V, Marcelin AG, Khatib AM. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. Int J Mol Sci. 2021 Feb 8;22(4):1695. doi: 10.3390/ijms22041695. PMID: 33567580.

Kactus Biosystems Co.Ltd
Online Message